Adenosine receptors in regulation of dendritic cell differentiation and function

Inflammation and cancer

Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111

Receptors for Purines and Pyrimidines

Burnstock, G., & Verkhratsky, A. (2012) · Springer eBooks · doi:10.1007/978-3-642-28863-0_5 · Cited by 3,962

International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors

Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585

Ido expression by dendritic cells: tolerance and tryptophan catabolism

Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341

Receptors for Purines and Pyrimidines

Ralevic, V., & Burnstock, G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01373-5 · Cited by 2,028

A2A adenosine receptor protects tumors from antitumor T cells

Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D. E., Wong, M. K. K., Huang, X., Caldwell, S. A., Liu, K., Smith, P. T., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,095

Adenosine: an endogenous regulator of innate immunity

Haskó, G. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 900

Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion

Zea, A. H., Rodrı́guez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D. F., Quiceno, D. G., Youmans, A. J., O’Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 852

Adenosine, an endogenous anti-inflammatory agent

Cronstein, B. N. (1994) · Journal of Applied Physiology · doi:10.1152/jappl.1994.76.1.5 · Cited by 633

Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells11Abbreviations: cAMP, cyclic adenosine 3′,5′-monophosphate; CHO, Chinese hamster ovary; NBMPR, nitrobenzylthioinosine; and NECA, 5′-N-ethyl carboxamido adenosine.

Fredholm, B. B., Irenius, E., Kull, B., & Schulte, G. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00570-0 · Cited by 430

Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment

Chiarella, A. M., Ryu, Y. K., Manji, G. A., & Rustgi, A. K. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.008 · Cited by 87

Adenosine receptor targeting in health and disease

Gessi, S., Merighi, S., Fazzi, D., Stefanelli, A., Varani, K., & Borea, P. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.627853 · Cited by 84

The Immune Regulatory Role of Adenosine in the Tumor Microenvironment

Xing, J., Zhang, J., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914928 · Cited by 96

Lifting the innate immune barriers to antitumor immunity

Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 83

Immunoregulatory activity of adenosine and its role in human cancer progression

Muller-Haegele, S., Müller, L., & Whiteside, T. L. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.915739 · Cited by 82

Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8+ T‐cell priming capacity

Challier, J., Bruniquel, D., Sewell, A. K., & Laugel, B. (2012) · Immunology · doi:10.1111/imm.12053 · Cited by 81

Role of Adenosine A2B Receptors in Inflammation

Feoktistov, I., & Biaggioni, I. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00005-9 · Cited by 80

Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy

Arab, S., & Hadjati, J. (2019) · Immune Network · doi:10.4110/in.2019.19.e23 · Cited by 87

Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches

Thompson, E. A., & Powell, J. D. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-023155 · Cited by 80

Adenosine in cancer immunotherapy: Taking off on a new plane

Zhang, C., Wang, K., & Wang, H. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189005 · Cited by 82

Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties

Novitskiy, S. V., Pickup, M. W., Chytil, A., Polosukhina, D., Owens, P., & Moses, H. L. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.1211639 · Cited by 79

CD73 is associated with poor prognosis in HNSCC

Ren, Z., Lin, C., Cao, W., Yang, R., Lu, W., Liu, Z., Chen, Y., Yang, X., Tian, Z., Wang, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11435 · Cited by 78

Innate immunity in allergic disease

Minnicozzi, M., Sawyer, R. T., & Fenton, M. J. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01025.x · Cited by 78

Protumor Activities of the Immune Response: Insights in the Mechanisms of Immunological Shift, Oncotraining, and Oncopromotion

Chimal-Ramírez, G. K., Espinoza‐Sánchez, N. A., & Fuentes‐Pananá, E. M. (2013) · Journal of Oncology · doi:10.1155/2013/835956 · Cited by 80

Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma

Wang, Z., Wang, Z., Li, B., Wang, S., Chen, T., & Ye, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01114 · Cited by 77

Gαs–Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant Gαs-PKA Signaling

Ramms, D. J., Raimondi, F., Arang, N., Herberg, F. W., Taylor, S. S., & Gutkind, J. S. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000269 · Cited by 73

Harnessing dendritic cells in cancer

Apétoh, L., Locher, C., Ghiringhelli, F., Kroemer, G., & Zitvogel, L. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.01.003 · Cited by 79

Pollen metabolome analysis reveals adenosine as a major regulator of dendritic cell–primed TH cell responses

Gilles, S., Fekete, Á., Zhang, X., Beck, I., Blume, C., Ring, J., Schmidt‐Weber, C. B., Behrendt, H., Schmitt‐Kopplin, P., & Traidl‐Hoffmann, C. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1082 · Cited by 71

Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy

Zhu, S., Yang, N., Wu, J., Wang, X., Wang, W., Liu, Y.-J., & Chen, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104980 · Cited by 71

The Clinical Significance of CD73 in Cancer

Bach, N., Winzer, R., Tolosa, E., Fiedler, W., & Brauneck, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411759 · Cited by 74

Adenosine metabolism, immunity and joint health

Haskó, G., Antonioli, L., & Cronstein, B. N. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.002 · Cited by 78

Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology

Valdés‐Mora, F., Handler, K., Law, A. M. K., Salomon, R., Oakes, S. R., Ormandy, C. J., & Gallego‐Ortega, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02582 · Cited by 69

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

Seitz, L. C., Jin, L., Leleti, M. R., Ashok, D., Jeffrey, J. L., Rieger, A., Tiessen, R. G., Arold, G., Tan, J. B. L., Powers, J. P., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0706-6 · Cited by 68

Extracellular adenosine metabolism in immune cells in melanoma

Umansky, V., Shevchenko, I., Bazhin, A. V., & Utikal, J. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1553-8 · Cited by 69

Myeloid cells in the tumor microenvironment: Role of adenosine

Morello, S., Pinto, A., Blandizzi, C., & Antonioli, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1108515 · Cited by 72

Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma

Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 69

Targeting adenosine and regulatory T cells in cancer immunotherapy

Churov, A. V., & Жулай, Г. А. (2021) · Human Immunology · doi:10.1016/j.humimm.2020.12.005 · Cited by 68

Reverting Immune Suppression to Enhance Cancer Immunotherapy

Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 71

Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development

Cheu, J. W.-S., Chiu, D. K.-C., Kwan, K. K.-L., Yang, C., Yuen, V. W.-H., Goh, C. C., Chui, N. N.-Q., Shen, W., Law, C.-T., Li, Q., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade5111 · Cited by 65

Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor

Arab, S., Kheshtchin, N., Ajami, M., Ashurpoor, M., Safvati, A., Namdar, A., Mirzaei, R., Mousavi-Niri, N., Jadidi‐Niaragh, F., Ghahremani, M. H., et al. (2017) · Tumor Biology · doi:10.1177/1010428317695021 · Cited by 64

Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints

Baghbani, E., Noorolyai, S., Shanehbandi, D., Mokhtarzadeh, A., Maleki, L. A., Khaze, V., Brunetti, O., Rahmani, S., Shadbad, M. A., Baghbanzadeh, A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119826 · Cited by 64

Nutritional Modulation of Immune and Central Nervous System Homeostasis: The Role of Diet in Development of Neuroinflammation and Neurological Disease

Estrada, J. A., & Contreras, I. (2019) · Nutrients · doi:10.3390/nu11051076 · Cited by 65

Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward

Jennings, M. R., Munn, D. H., & Blazeck, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003013 · Cited by 64

Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints

Hargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 63

Role of adenosine A2b receptor overexpression in tumor progression

Sepúlveda, C., Palomo, I. F., & Eduardo Fuentes, Q. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.10.008 · Cited by 65

Regulation of Leukocyte Function by Adenosine Receptors

Linden, J. M. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00004-7 · Cited by 60

Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy

Biktasova, A. K., Dudimah, D. F., Uzhachenko, R. V., Park, K., Akhter, A., Arasada, R. R., Evans, J. V., Novitskiy, S. V., Tchekneva, E. E., Carbone, D. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1154 · Cited by 59

Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner

Tang, T., Huang, X., Lu, M., Zhang, G., Han, X., & Liang, T. (2023) · Nature Communications · doi:10.1038/s41467-023-38578-3 · Cited by 62

Hepatic Dendritic Cells, the Tolerogenic Liver Environment, and Liver Disease

Dou, L., Ono, Y., Chen, Y.-F., Chen, X., & Thomson, A. W. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1646949 · Cited by 60

The adenosine A2B G protein-coupled receptor: Recent advances and therapeutic implications

Vecchio, E. A., White, P. J., & May, L. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.01.003 · Cited by 57

Attenuation of Chronic Pulmonary Inflammation in A2B Adenosine Receptor Knockout Mice

Zaynagetdinov, R., Ryzhov, S. V., Goldstein, A. E., Yin, H., Novitskiy, S. V., Goleniewska, K., Polosukhin, V. V., Newcomb, D. C., Mitchell, D. B., Morschl, É., et al. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0391oc · Cited by 54

Adenosinergic signaling as a target for natural killer cell immunotherapy

Wang, J., & Matosevic, S. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1679-9 · Cited by 53

Targeting adenosine A2A receptor antagonism for treatment of cancer

Congreve, M., Brown, G. A., Borodovsky, A., & Lamb, M. L. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1534825 · Cited by 54

Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity

Tchekneva, E. E., Goruganthu, M., Uzhachenko, R. V., Thomas, P. L., Antonucci, A., Chekneva, I. S., Koenig, M. J., Piao, L., Akhter, A., de Aquino, M. T. P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0566-4 · Cited by 54

Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance

Vautrot, V., Bentayeb, H., Causse, S., Garrido, C., & Gobbo, J. (2021) · Cancers · doi:10.3390/cancers13184537 · Cited by 55

Modification of the Tumor Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics

Finke, J. H., Rayman, P. A., Ko, J. S., Bradley, J. M., Gendler, S. J., & Cohen, P. A. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829da0ae · Cited by 52

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy

Kurago, Z., Guo, G. F., Shi, H., Bollag, R. J., Groves, M., Byrd, J. K., & Cui, Y. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212209 · Cited by 50

The adenosinergic immunomodulatory drugs

Ohta, A., & Sitkovsky, M. V. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.05.005 · Cited by 51

Regulation Generation: The Suppressive Functions of Human Regulatory T Cells

Goodman, W. A., Cooper, K. D., & McCormick, T. S. (2012) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v32.i1.40 · Cited by 52

Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 50

The progress and prospects of targeting the adenosine pathway in cancer immunotherapy

Yang, Y., Zhu, L., Xu, Y., Liang, L., Liu, L.-Z., Chen, X., Li, H., & Liu, H. (2025) · Biomarker Research · doi:10.1186/s40364-025-00784-0 · Cited by 55

Inflammation related responses of intestinal cells to plum and cabbage digesta with differential carotenoid and polyphenol profiles following simulated gastrointestinal digestion

Kaulmann, A., Legay, S., Schneider, Y., Hoffmann, L., & Bohn, T. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500947 · Cited by 50

Immunosuppressive enzymes in the tumor microenvironment

Molinier‐Frenkel, V., & Castellano, F. (2017) · FEBS Letters · doi:10.1002/1873-3468.12784 · Cited by 53

Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer

Chabab, G., Barjon, C., Abdellaoui, N., Salvador-Prince, L., Déjou, C., Michaud, H., Boissière‐Michot, F., Lopez‐Crapez, E., Jacot, W., Pourquier, D., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ma0420-278rr · Cited by 53

The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies

Wang, L., Zhang, J., Zhang, W., Zheng, M., Guo, H., Pan, X., Li, W., Yang, B., & Ding, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.004 · Cited by 56

Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer

Sitkovsky, M. V., & Ohta, A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1001-9 · Cited by 51

Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors

Sciaraffia, E., Riccomi, A., Lindstedt, R., Gesa, V., Cirelli, E., Patrizio, M., Magistris, M. T. D., & Vendetti, S. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0513-302rr · Cited by 49

Immunometabolism in the Tumor Microenvironment

Roy, D. G., Kaymak, I., Williams, K. S., Ma, E. H., & Jones, R. G. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055817 · Cited by 49

Role of adenosine A2a receptor in cancers and autoimmune diseases

Ye, H., Zhao, J.-Q., Xu, X., Zhang, D., Shen, H., & Wang, S. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.826 · Cited by 55

Adenosine and gastrointestinal inflammation

Colgan, S. P., Fennimore, B. P., & Ehrentraut, S. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0990-0 · Cited by 47

Immunotherapeutic strategies in kidney cancer—when TKIs are not enough

Biswas, S., & Eisen, T. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.91 · Cited by 47

Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?

Dunavin, N., Dias, A., Li, M., & McGuirk, J. P. (2017) · Biomedicines · doi:10.3390/biomedicines5030039 · Cited by 45

Impact of immune cells on the hallmarks of cancer: A literature review

Costa, A. C., Santos, J., da Costa, R. M. G., & Medeiros, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103541 · Cited by 48

Leishmania amazonensis impairs DC function by inhibiting CD 40 expression via A 2B adenosine receptor activation

Figueiredo, A. B., Serafim, T. D., da Silva, E. D. A. M., Meyer‐Fernandes, J. R., & Afonso, L. (2012) · European Journal of Immunology · doi:10.1002/eji.201141926 · Cited by 45

Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection

Passos, D. F., Bernardes, V. M., da Silva, J. L. G., Schetinger, M. R. C., & Leal, D. B. R. (2018) · Purinergic Signalling · doi:10.1007/s11302-018-9619-2 · Cited by 43

The Pollen Enigma: Modulation of the Allergic Immune Response by Non-Allergenic, Pollen-Derived Compounds

Gilles, S., Behrendt, H., Ring, J., & Traidl‐Hoffmann, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800166040 · Cited by 42

ATP confers tumorigenic properties to dendritic cells by inducing amphiregulin secretion

Bles, N., di Pietrantonio, L., Boeynaems, J., & Communi, D. (2010) · Blood · doi:10.1182/blood-2010-01-265611 · Cited by 42

Ligand-Specific Binding and Activation of the Human Adenosine A2BReceptor

Thimm, D., Schiedel, A. C., Sherbiny, F. F., Hinz, S., Hochheiser, K., Bertarelli, D. C. G., Maaß, A., & Müller, C. E. (2013) · Biochemistry · doi:10.1021/bi3012065 · Cited by 42

Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms

Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41

Dendritic cell subsets and implications for cancer immunotherapy

Chen, M. Y., Zhang, F., Goedegebuure, S. P., & Gillanders, W. E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393451 · Cited by 44

Investigational A3adenosine receptor targeting agents

Koscsó, B., Csóka, B., Pacher, P., & Haskó, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.573785 · Cited by 41

Inflammation and Myeloid Cells in Cancer Progression and Metastasis

Deng, J., & Fleming, J. B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.759691 · Cited by 44

The Colon Cancer Stem Cell Microenvironment Holds Keys to Future Cancer Therapy

Chen, S., & Huang, E. H. (2014) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-014-2497-1 · Cited by 39

The Effect of the Tumor Microenvironment and Tumor-Derived Metabolites on Dendritic Cell Function

Lee, J., Choi, S.-Y., Jung, N.-C., Song, J. Y., Seo, H. G., Lee, H. S., & Lim, D. (2019) · Journal of Cancer · doi:10.7150/jca.38785 · Cited by 41

The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates

Mohamed, E. T., Al-Khami, A. A., & Rodrı́guez, P. C. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0001-7 · Cited by 39

Neonatal pneumococcal conjugate vaccine immunization primes T cells for preferential Th2 cytokine expression: A randomized controlled trial in Papua New Guinea

van den Biggelaar, A. H. J., Richmond, P., Pomat, W. S., Phuanukoonnon, S., Nadal-Sims, M. A., Devitt, C. J., Siba, P. M., Lehmann, D., & Holt, P. G. (2009) · Vaccine · doi:10.1016/j.vaccine.2008.12.046 · Cited by 39

Oxygen-dependent regulation of immune checkpoint mechanisms

Ohta, A. (2018) · International Immunology · doi:10.1093/intimm/dxy038 · Cited by 38

Downregulation of CD73 associates with T cell exhaustion in AML patients

Kong, Y., Jia, B., Zhao, C., Claxton, D. F., Sharma, A. K., Annageldiyev, C., Fotos, J. S., Zeng, H., Paulson, R. F., Prabhu, K. S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0728-3 · Cited by 38

CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma

Jeong, Y. M., Cho, H. J., Kim, T., Kim, Y., Jeon, S., Bychkov, A., & Jung, C. K. (2020) · Cancers · doi:10.3390/cancers12103042 · Cited by 38

Anti-Inflammatory or Proinflammatory Effect of an Adenosine Receptor Agonist on the Th17 Autoimmune Response Is Inflammatory Environment–Dependent

Liang, D., Zuo, A., Shao, H., Chen, M., Kaplan, H. J., & Sun, D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401959 · Cited by 37

Adenosine receptors differentially regulate type 2 cytokine production by IL‐33–activated bone marrow cells, ILC2s, and macrophages

Csóka, B., Németh, Z. H., Duerr, C. U., Fritz, J. H., Pacher, P., & Haskó, G. (2017) · The FASEB Journal · doi:10.1096/fj.201700770r · Cited by 38

Adenosine Signaling in Autoimmune Disorders

Magni, G., & Ceruti, S. (2020) · Pharmaceuticals · doi:10.3390/ph13090260 · Cited by 37

Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function

Wang, Y., Zhang, K. X., Georgiev, P., Wells, S. B., Xu, H., Lacey, B. M., Xu, Z., Laskey, J., McLeod, R. L., Methot, J. L., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243145 · Cited by 37

Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer

Lim, J. U., Lee, E., Lee, S., Cho, H. J., Ahn, D. H., Hwang, Y., Choi, J. Y., Yeo, C. D., Park, C. K., & Kim, S. J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-633 · Cited by 36

Role of the Sympathetic Nervous System in Mild Chronic Inflammatory Diseases: Focus on Osteoarthritis

Sohn, R. E., & Jenei‐Lanzl, Z. (2023) · NeuroImmunoModulation · doi:10.1159/000531798 · Cited by 37

Metabolic reprogramming of myeloid-derived suppressor cells: An innovative approach confronting challenges

Li, X., Li, Y., Yu, Q., Qian, P., Huang, H., & Lin, Y. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0421-597rr · Cited by 36

Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies

Zahavi, D. J., & Hodge, J. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108871 · Cited by 38

Immunometabolic reprogramming, another cancer hallmark

Kumar, V., & Stewart, J. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125874 · Cited by 37

Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status

Schlicher, L., Green, L. G., Romagnani, A., & Renner, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1297175 · Cited by 34

Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets

Vaisitti, T., Arruga, F., Guerra, G., & Deaglio, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02301 · Cited by 36

The role of Th17-associated cytokines in the pathogenesis of experimental autoimmune uveitis (EAU)

Sun, D., Liang, D., Kaplan, H. J., & Shao, H. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.017 · Cited by 36

Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review

Wang, R., Zhang, Y., Xia, L., Gao, Y., & Zhu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.16905 · Cited by 35

Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK)

Liu, J., Chen, W., Meng, J., Lu, C., Wang, E., & Shan, F. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1221-9 · Cited by 34

An A2B Adenosine Receptor Agonist Promotes Th17 Autoimmune Responses in Experimental Autoimmune Uveitis (EAU) via Dendritic Cell Activation

Chen, M., Liang, D., Zuo, A., Shao, H., Kaplan, H. J., & Sun, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132348 · Cited by 34

cAMP During HIV Infection: Friend or Foe?

Moreno‐Fernandez, M. E., Rueda, C. M., Velilla, P. A., Rugeles, M. T., & Chougnet, C. A. (2011) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0265 · Cited by 33

Roles of the Adenosine Receptor and CD73 in the Regulatory Effect of γδ T Cells

Liang, D., Zuo, A., Shao, H., Chen, M., Kaplan, H. J., & Sun, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108932 · Cited by 33

Role of JunB in Adenosine A2B Receptor–Mediated Vascular Endothelial Growth Factor Production

Ryzhov, S. V., Biktasova, A., Goldstein, A. E., Zhang, Q., Biaggioni, I., Dikov, M. M., & Feoktistov, I. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.088567 · Cited by 33

A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling

Hasan, D., Shono, A., van Kalken, C. K., van der Spek, P. J., Krenning, E. P., & Kotani, T. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09814-6 · Cited by 35

Metabolic guidance and stress in tumors modulate antigen-presenting cells

Park, J., Wang, L., & Ho, P. (2022) · Oncogenesis · doi:10.1038/s41389-022-00438-y · Cited by 33

Cladribine exerts an immunomodulatory effect on human and murine dendritic cells

Kraus, S. H. P., Luessi, F., Trinschek, B., Lerch, S., Hubo, M., Poisa-Beiro, L., Paterka, M., Jonuleit, H., Zipp, F., & Jolivel, V. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.11.027 · Cited by 33

IMMUNOBIOLOGY Adenosine receptors in regulation of dendritic cell differentiation and function

Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., et al. (2016)

Adenosine A 2B receptors in regulation of dendritic cell differentiation and function

Ryzhov, S. V., Novitskiy, S. V., Zaynagetdinov, R., Goldstein, A. E., Biaggioni, I., Carbone, D. P., Feoktistov, I., & Dikov, M. M. (2008) · The FASEB Journal · doi:10.1096/fasebj.22.1_supplement.1065.34 · Cited by 2

The A2B Adenosine Receptor Promotes Th17 Differentiation via Stimulation of Dendritic Cell IL-6

Wilson, J. M., Kurtz, C. C., Black, S. G., Ross, W. G., Alam, M. S., Linden, J. M., & Ernst, P. B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100117 · Cited by 97

Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8+ T‐cell priming capacity

Challier, J., Bruniquel, D., Sewell, A. K., & Laugel, B. (2012) · Immunology · doi:10.1111/imm.12053 · Cited by 81

Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells

Panther, E., Corinti, S., Idzko, M., Herouy, Y., Napp, M., la Sala, A., Girolomoni, G., & Norgauer, J. (2003) · Blood · doi:10.1182/blood-2002-07-2113 · Cited by 229